Uda H - Search Results

1

Adult Still's disease reflects a Th2 rather than a Th1 cytokine profile.

Saiki O, Uda H, Nishimoto N, Miwa T, Mima T, Ogawara T, Azuma N, Katada Y, Sawaki J, Tsutsui H, Matsui K, Maeda A, Nakanishi K. Saiki O, et al. Among authors: uda h. Clin Immunol. 2004 Jul;112(1):120-5. doi: 10.1016/j.clim.2004.03.023. Clin Immunol. 2004. PMID: 15207789

2

Ratio of serum amyloid A to C-reactive protein is constant in the same patients but differs greatly between patients with inflammatory diseases.

Saiki O, Uda H. Saiki O, et al. Among authors: uda h. Scand J Immunol. 2022 Feb;95(2):e13121. doi: 10.1111/sji.13121. Epub 2021 Nov 24. Scand J Immunol. 2022. PMID: 34796986 Free article.

3

Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis.

Saiki O, Takao R, Naruse Y, Kuhara M, Imai S, Uda H. Saiki O, et al. Among authors: uda h. J Rheumatol. 2007 Oct;34(10):1997-2004. Epub 2007 Sep 1. J Rheumatol. 2007. PMID: 17787045

4

Efficacy and safety of extending intravenous tocilizumab intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals.

Saiki O, Uda H. Saiki O, et al. Among authors: uda h. Rheumatol Int. 2018 Dec;38(12):2307-2313. doi: 10.1007/s00296-018-4149-3. Epub 2018 Sep 11. Rheumatol Int. 2018. PMID: 30206670

5

Expansion of a CD28-intermediate subset among CD8 T cells in patients with infectious mononucleosis.

Uda H, Mima T, Yamaguchi N, Katada Y, Fukuda M, Fujii N, Nakamura K, Saiki O. Uda H, et al. J Virol. 2002 Jul;76(13):6602-8. doi: 10.1128/jvi.76.13.6602-6608.2002. J Virol. 2002. PMID: 12050373 Free PMC article.

6

Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis.

Uda H, Yokota A, Kobayashi K, Miyake T, Fushimi H, Maeda A, Saiki O. Uda H, et al. J Rheumatol. 2006 Aug;33(8):1482-7. J Rheumatol. 2006. PMID: 16881107

7

In vivo but not in vitro stimulations rescue of the defective class switching to IgG or IgA in B-cells of immunodeficiency with hyper IgM.

Saiki O, Uda H, Hayashi M, Tanaka T, Katada Y, Shimizu M, Kinoshita N, Kishimoto T. Saiki O, et al. Among authors: uda h. Clin Immunol Immunopathol. 1997 Jun;83(3):287-92. doi: 10.1006/clin.1997.4349. Clin Immunol Immunopathol. 1997. PMID: 9175918

8

Tocilizumab postpones the start of hemodialysis compared to conventional oral treatment in amyloid A amyloidosis patients with advanced renal insufficiency by suppressing serum SAA levels.

Uda H, Saiki O. Uda H, et al. Amyloid. 2017 Mar;24(1):62-63. doi: 10.1080/13506129.2017.1301420. Epub 2017 Apr 10. Amyloid. 2017. PMID: 28393636 No abstract available.

9

Successful extension of tocilizumab infusion intervals from 4 weeks to 6 or 5 weeks in 90% of RA patients with good response to 4-week intervals.

Saiki O, Uda H. Saiki O, et al. Among authors: uda h. Clin Exp Rheumatol. 2017 Jul-Aug;35(4):666-670. Epub 2017 Feb 20. Clin Exp Rheumatol. 2017. PMID: 28229812

10

Signaling through CD40 rescues IgE but not IgG or IgA secretion in X-linked immunodeficiency with hyper-IgM.

Saiki O, Tanaka T, Wada Y, Uda H, Inoue A, Katada Y, Izeki M, Iwata M, Nunoi H, Matsuda I, et al. Saiki O, et al. Among authors: uda h. J Clin Invest. 1995 Feb;95(2):510-4. doi: 10.1172/JCI117692. J Clin Invest. 1995. PMID: 7532185 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

195 results

Search Page

Filters